Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 30 and 80 inclusive.~* Has not worn contact lenses for at least 1 month prior to the study and agrees to not wear contact lenses during study.~* Oral medications stable 1 month prior to study.~* Oral medications anticipated to be stable during 60 day study.~* Patient is in generally good \& stable overall health.~* Patient likely to comply with eye drop regimen, study guidelines \& study visits.~* Corneal stain \> 1+ or Conjunctival stain \> 1+ or OSDI equal or \> 5 or using regular artificial tears at least on average twice daily.~* Informed consent signed.~Exclusion Criteria:~* History of Stevens-Johnson Syndrome or Ocular Pemphigoid.~* Punctal plugs inserted or punctal cautery in the past 3 months.~* Intra-ocular surgery within 6 months or ocular laser surgery within 3 months.~* History of liver disease.~* Pregnant or lactating women.~* Severe clinical vitamin deficiencies or history of vitamin overdose.~* Highly variable vitamin intake.~* Unstable use of systemic or topical medications known to create dry eye.~* Corneal pathology, which could, of itself, cause an ocular surface disorder.~* Use of glaucoma medications, topical or oral.~* Unstable diabetes mellitus.~* Allergy or sensitivity to Lotemax, Restasis or the OTC Tear Supplement.~* Use of topical steroids or Restasis within the past 1 month.~* Use of other topical ocular agents other than tear replacements within the past 1 week.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).